宜明昂科：IMM2510/AXN-2510用于治疗实体肿瘤获美国FDA临床试验批准

Core Viewpoint - The company has received approval from the U.S. Food and Drug Administration (FDA) for a new drug clinical trial (IND) for IMM2510/AXN-2510, which is expected to start by the end of 2025 [1] Group 1 - The clinical trial is a Phase 1b/2 study aimed at evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of IMM2510/AXN-2510 in patients with recurrent/refractory solid tumors [1]